The next-generation sequencing and histopathological studies of tumor and control tissues suggesting the overexpression of wild-type survivin in the tumor tissues provide clear evidence of developing new CTL immunotherapy treatments for DCIS [58]. Here, BIRC5 is linked to ductal breast carcinoma in situ.